CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −150 | $448.77 | $67K | 27,379 |
| 2025-10-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −207 | $449.79 | $93K | 27,172 |
| 2025-10-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −449 | $450.81 | $202K | 26,723 |
| 2025-10-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −276 | $451.86 | $125K | 26,447 |
| 2025-10-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −555 | $452.69 | $251K | 25,892 |
| 2025-10-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −273 | $453.77 | $124K | 25,619 |
| 2025-10-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −203 | $454.84 | $92K | 25,416 |
| 2025-10-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −60 | $455.82 | $27K | 25,356 |
| 2025-10-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −122 | $457.43 | $56K | 25,234 |
| 2025-10-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −3 | $457.64 | $1K | 25,231 |
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −115 | $446.53 | $51K | 26,065 |
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −56 | $447.92 | $25K | 26,009 |
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −180 | $448.77 | $81K | 25,829 |
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −249 | $449.79 | $112K | 25,580 |
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −541 | $450.81 | $244K | 25,039 |
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −332 | $451.86 | $150K | 24,707 |
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −668 | $452.69 | $302K | 24,039 |
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −329 | $453.77 | $149K | 23,710 |
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −244 | $454.84 | $111K | 23,466 |
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −73 | $455.82 | $33K | 23,393 |
Page 21 of 41 · 816 trades